Combivent Respimat

Hyperkalemia, Acute Bronchitis, Pneumonia + 18 more

Treatment

9 FDA approvals

20 Active Studies for Combivent Respimat

What is Combivent Respimat

Salbutamol

The Generic name of this drug

Treatment Summary

Salbutamol is a medication that helps to open up the airways in people with asthma or COPD. It works by stimulating beta2-adrenergic receptors, which are located in the lungs, more than the beta1-adrenergic receptors in the heart. Salbutamol is a mixture of two isomers, R- and S-isomers, and the R-isomer has 150 times greater affinity for the beta2-receptor. A single R-isomer version of salbutamol, levalbuterol, was developed, but it is more expensive than salbutamol,

Proair HFA

is the brand name

image of different drug pills on a surface

Combivent Respimat Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Proair HFA

Salbutamol

1981

314

Approved as Treatment by the FDA

Salbutamol, also known as Proair HFA, is approved by the FDA for 9 uses like prophylaxis of Exercise-induced bronchospasm and prophylaxis of Bronchospasm .

prophylaxis of Exercise-induced bronchospasm

prophylaxis of Bronchospasm

Bronchospasm, Exercise-Induced

Bronchial Spasm

Asthma, Exercise-Induced

Chronic Obstructive Pulmonary Disease

Used to treat Chronic Obstructive Pulmonary Disease (COPD) in combination with Ipratropium

Bronchodilator Agents

Used to treat need of more than one bronchodilator in combination with Ipratropium

Exercise-Induced Bronchospasm

Bronchospasm

Effectiveness

How Combivent Respimat Affects Patients

Salbutamol (also known as albuterol) is a medicine used to open up airways and make breathing easier. It works by stimulating beta-1 and beta-2 receptors in the body, which can result in increased heart rate and relaxed muscles. Taking salbutamol can also cause changes in blood sugar and insulin levels. Additionally, it can cause potassium levels in the blood to drop. Levalbuterol is a related medication that contains only the R-enantiomer of salbutamol, and may have fewer side effects.

How Combivent Respimat works in the body

Salbutamol is a medication that relaxes the airways in the lungs. It works by activating beta2-adrenergic receptors, which then increases cyclic-3′,5′-adenosine monophosphate (cyclic AMP) levels. This increase in cyclic AMP leads to the relaxation of the smooth muscles in the airways, allowing air to flow more easily. Salbutamol also inhibits the release of mediators from mast cells in the airways. Compared to similar medications, salbutamol has fewer cardiovascular effects. When inhaled, salbutamol usually starts to work

When to interrupt dosage

The quantity of Combivent Respimat is contingent upon the diagnosed condition, like Bronchodilator Agents, Emphysema and Wheezing. The dosage fluctuates based on the method of delivery specified in the table below.

Condition

Dosage

Administration

Pneumonia

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Airway secretion clearance therapy

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Emphysema

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Hyperkalemia

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Acute Bronchitis

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Bronchial Spasm

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Asthma

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Respiratory Tract Infections

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Influenza

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Asthma

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Bronchodilator Agents

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Bronchitis

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Bronchitis, Chronic

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Asthma, Exercise-Induced

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Asthma

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

prophylaxis of Bronchospasm

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Bronchodilation

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

excess mucus or phlegm

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Bronchospasm, Exercise-Induced

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Chronic Obstructive Pulmonary Disease

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Oral, Solution - Intramuscular, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Warnings

There are 20 known major drug interactions with Combivent Respimat.

Common Combivent Respimat Drug Interactions

Drug Name

Risk Level

Description

Hydroxyzine

Major

The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Hydroxyzine.

Mobocertinib

Major

The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Mobocertinib.

Ziprasidone

Major

The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ziprasidone.

1-benzylimidazole

Minor

The risk or severity of hypertension can be increased when Salbutamol is combined with 1-benzylimidazole.

2,5-Dimethoxy-4-ethylamphetamine

Minor

The risk or severity of hypertension can be increased when Salbutamol is combined with 2,5-Dimethoxy-4-ethylamphetamine.

Combivent Respimat Toxicity & Overdose Risk

Taking too much albuterol can cause side effects like rapid heart rate, high or low blood pressure, shaking, headache, dry mouth, nausea, dizziness, fatigue, trouble sleeping, and low potassium levels. Taking albuterol while pregnant may cause birth defects. Albuterol is not recommended for children under 4 years old. The most toxic dose of albuterol in mice has been determined to be 1100mg/kg.

image of a doctor in a lab doing drug, clinical research

Combivent Respimat Novel Uses: Which Conditions Have a Clinical Trial Featuring Combivent Respimat?

383 studies are currently in progress to assess the potential of Combivent Respimat to ameliorate Respiratory Tract Infections, Asthma and Chronic Obstructive Pulmonary Disease (COPD).

Condition

Clinical Trials

Trial Phases

Bronchospasm, Exercise-Induced

0 Actively Recruiting

Chronic Obstructive Pulmonary Disease

72 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Asthma

87 Actively Recruiting

Phase 1, Phase 4, Early Phase 1, Not Applicable, Phase 2, Phase 3

prophylaxis of Bronchospasm

0 Actively Recruiting

Influenza

28 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 1, Phase 3

Hyperkalemia

4 Actively Recruiting

Phase 3, Not Applicable, Phase 2, Phase 1

Bronchitis, Chronic

0 Actively Recruiting

excess mucus or phlegm

0 Actively Recruiting

Bronchodilator Agents

0 Actively Recruiting

Pneumonia

17 Actively Recruiting

Not Applicable, Early Phase 1, Phase 2, Phase 4

Bronchial Spasm

0 Actively Recruiting

Asthma

1 Actively Recruiting

Phase 2

Airway secretion clearance therapy

0 Actively Recruiting

Respiratory Sounds

4 Actively Recruiting

Phase 2, Phase 3

Asthma

1 Actively Recruiting

Phase 4

Asthma, Exercise-Induced

0 Actively Recruiting

Emphysema

4 Actively Recruiting

Phase 2, Not Applicable

Bronchitis

0 Actively Recruiting

Acute Bronchitis

8 Actively Recruiting

Phase 4, Not Applicable, Phase 3, Early Phase 1

Bronchodilation

0 Actively Recruiting

Combivent Respimat Reviews: What are patients saying about Combivent Respimat?

5

Patient Review

1/15/2020

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I have two of these that I don't need anymore. If anyone in the Austin area is interested, please let me know.

5

Patient Review

1/15/2020

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I have two brand new ones and one that's almost new. I don't need them anymore. If anybody is needing these, I'm willing to sale to try and get some of my money back 5126074137

5

Patient Review

4/6/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

5

Patient Review

5/10/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

5

Patient Review

4/6/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

5

Patient Review

5/10/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

4.3

Patient Review

7/18/2019

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I switched to this inhaler a month ago, and I'm really pleased with it. It feels like it gives me more breath than my old one did, which is great now that I've quit smoking.

4.3

Patient Review

7/18/2019

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I switched to this inhaler about a month ago, and I find that it gives me more breath than my previous inhaler.

4

Patient Review

3/10/2017

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I wasn't thrilled with the design or performance of this product, but it did work half the time. The dosing was also inconsistent, which is frustrating. That said, I know people who have had success with this treatment, so maybe it's just me.

4

Patient Review

10/5/2019

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

This works better than my straight albuterol inhaler.

4

Patient Review

3/10/2017

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

This product is unfortunately ineffective much of the time, and when it does work, it doesn't deliver the full amount of medication. On top of that, it's expensive! I would not recommend this product to anyone.

4

Patient Review

10/5/2019

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

This works better than a traditional albuterol inhaler for me.

3.7

Patient Review

6/16/2018

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I've been having issues with Combivent Respimat not lasting a full month, as it's only supposed to have 120 doses. In 2017, it averaged less than 25 days, and in May-June 2018, it barely lasted two weeks. I contacted the company but nothing changed.

3.7

Patient Review

6/16/2018

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I have had continuing problems with Combivent Respimat. It is supposed to have 120 doses for the month but has typically not lasted a full month. Last year 2017 it averaged less than 25 days. For May and June of 2018 it barely lasts two weeks and I am left without medication for the remainder of the month. Something is wrong with this product.

3.3

Patient Review

11/21/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I wouldn't exactly call this an effective medication. It's tough to use and I cough as soon as I take it, so who knows how much of the dose I'm actually getting? If something isn't broken, there's no need to try and fix it.

3.3

Patient Review

11/21/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I was very disappointed with this product. It didn't work for me, was difficult to use, and made me cough. I don't understand why they felt the need to change a medication that wasn't broken in the first place.

2

Patient Review

10/4/2019

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

The price is very high.

2

Patient Review

7/16/2022

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I've only just started using Combivent Respirtory, but my chest feels awful. It's like there's a fire inside. My bronchial tubes are really sore too. I'm 86 years old, and I hope there's something better out there for people in my situation.

2

Patient Review

7/16/2022

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I recently started using Combivent Respiators and have not had a good experience so far. My chest feels like it's on fire, and my bronchial tubes are sore. I'm 86 years old, female, and I feel like there must be something better out there for me.

2

Patient Review

10/4/2019

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

The price is really high.

1.7

Patient Review

6/8/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

The new inhaler is much more effective and easier to use. I don't have to lug around one of those tubes anymore.

1.7

Patient Review

6/8/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

The new inhaler is much more effective, in my opinion. With the old one, I had to use a separate tube to make sure I got the full dose--which was inconvenient.

1.3

Patient Review

12/11/2020

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I found this product to be ineffective. It didn't help me breathe any better, and I was actually winded from trying to use it. Definitely not worth your time or money.

1.3

Patient Review

4/21/2016

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

Though I need to take this more often for it to be effective, my doctor has advised against it.

1.3

Patient Review

12/11/2020

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I found this treatment to be ineffective. It didn't help me breathe at all, and I was just as winded after using it.

1.3

Patient Review

4/21/2016

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I would need to take this more often if it weren't for my doctor's advisement.

1

Patient Review

6/28/2018

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I was given this medication by the VA a few months ago as a replacement for Atrovent, which is no longer available. I have found that since taking Combivent Respimat, I am more short winded than before. Additionally, I now have to do nebulizer treatments constantly. I would much rather take Atrovent back.

1

Patient Review

6/28/2018

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I was on COPD inhalers since 2008 and they worked fine for me. Recently, the VA told me that Atrovent wasn't available anymore and gave me Combivent Respimat as a replacement. I have found that I am more short winded after taking it and constantly have to do nebulizer treatments now.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about combivent respimat

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is COMBIVENT RESPIMAT a rescue inhaler?

"Symbicort is also approved to treat asthma in adults and children ages 6 years and older. However, it is not meant to be used as a rescue medication for COPD for immediate breathing relief."

Answered by AI

Is combivent the same as albuterol?

"Combivent Respimat is used to treat chronic obstructive pulmonary disease (COPD). Albuterol sulfate is used to treat or prevent bronchospasm in people with reversible obstructive airway disease. Albuterol is also used as a preventative measure against exercise-induced bronchospasm."

Answered by AI

Is COMBIVENT RESPIMAT a steroid inhaler?

"No, Combivent Respimat (ipratropium / albuterol) is not a steroid. It contains two medications that help relax and open up the airways in your lungs. It works differently from steroids, which help to reduce inflammation (swelling) in the lungs."

Answered by AI

What is COMBIVENT RESPIMAT inhaler used for?

"This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease, such as bronchitis and emphysema. This product contains 2 medications: ipratropium and albuterol (also known as salbutamol)."

Answered by AI

Clinical Trials for Combivent Respimat

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17
All Sexes
Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4
Waitlist Available

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Have you considered Combivent Respimat clinical trials?

We made a collection of clinical trials featuring Combivent Respimat, we think they might fit your search criteria.
Go to Trials
Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+
All Sexes
Stanford, CA

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.

Waitlist Available
Has No Placebo

Stanford University

Jeff Swigris, DO, MS

Minnesota Health Solutions

Have you considered Combivent Respimat clinical trials?

We made a collection of clinical trials featuring Combivent Respimat, we think they might fit your search criteria.
Go to Trials
Image of National Institutes of Health Clinical Center in Bethesda, United States.

BPL-1357 for Flu

18 - 55
All Sexes
Bethesda, MD

Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it. Current vaccines protect against seasonal flus, but broader vaccines are needed to protect against potential flu pandemics. Objective: To test an experimental flu vaccine. Eligibility: Healthy people aged 18 to 55 years. Design: The study will last 5 to 8 months and has 2 phases, A and B. The study vaccine will be given either as a shot in the arm or as a nasal spray. Participants will receive 1 of 3 combinations: (1) study vaccine in the nose and placebo in the arm; (2) placebo in the nose and study vaccine in the arm; or (3) placebo in the nose and placebo in the arm. A placebo is just like the real vaccine but contains no active ingredients. Phase A: Participants will have 5 clinic visits over 56 days. They will receive a shot and a nasal spray at 2 of the visits, 28 days apart. At each visit, they will have a physical exam, with tests of their blood, urine, and nasal secretions. They will check their temperature at home and record any symptoms for 7 days after each vaccine. Phase B: Participants will stay in the hospital for at least 9 days. They will be infected with a flu virus. They will provide blood, urine, and nasal fluid samples. They will have tests of their heart function. They will remain in the hospital until they test negative for the flu 2 days in a row. They will have 2 follow-up visits, 4 and 8 weeks after leaving the hospital.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center (+1 Sites)

Luca T Giurgea, M.D.

Image of Vanderbilt University Medical Center in Nashville, United States.

High vs. Standard Dose Influenza Vaccines for Flu

18+
All Sexes
Nashville, TN

This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center. Lung transplantation is a life-saving therapy for patients with advanced lung disease, and is also associated with an improvement in quality of life. However, due to the need for life-long immunosuppression to prevent acute cellular rejection and chronic lung allograft dysfunction ("chronic rejection"), lung transplant recipients are at risk for developing major infections. In fact, one-year survival is 85%, with infection being the leading cause of death within the first year post-transplant. We will conduct a follow-up phase II, randomized, double-blind trial to assess the impact of subsequent administration of two doses of HD-IIV compared to two doses of SD-IIV among lung recipients during the early post-transplant period. Demonstration of improved immunogenicity from two doses of HD-IIV over consecutive influenza seasons would provide potential broad benefit in reducing influenza disease and its associated complications in lung transplant recipients. Moreover, studying vaccine immunogenicity and safety in the same participants over consecutive years can provide insight into the influence of immunosuppression levels and allograft aging on vaccine-mediated immune modulation. This proposed study design will contribute significantly to influenza vaccination guidance and policy for the highly vulnerable lung transplant population. This proposed study is designed to address several key knowledge gaps in vaccine-mediated protection of lung transplant recipients against influenza: * Is there increased immunogenicity with administration of one or two doses of HD-IIV or SD-IIV in the subsequent season compared to two doses of HD-IIV or SD-IIV in the first season? * What is the durability of the humoral and cellular immune response between influenza seasons and does two doses of HD-IIV or SD-IIV sustain higher HAI titers compared to two doses of HD-IIV or SD-IIV in the first season? * What is the impact of maintenance immunosuppression levels on influenza vaccine immunogenicity within the same participant? * Will the optimal immunogenic vaccination strategy be associated with an acceptable long-term safety profile over successive influenza seasons, including injection-site and systemic reactions, allosensitization, and organ rejection?

Phase 2
Recruiting

Vanderbilt University Medical Center

Natahsa Halasa, MD, MPH

Have you considered Combivent Respimat clinical trials?

We made a collection of clinical trials featuring Combivent Respimat, we think they might fit your search criteria.
Go to Trials